Process of drug registration in Israel: The correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA

Stephany Hiayev, Einat Shacham-Shmueli, Matitiahu Berkovitch, Ilana Weiss, Shai Ashkenazi, Michal Hirsch Vexberg, Rami Hershkowitz, Einat Gorelik, Haim Mayan, Yehudit Steinmetz, Noa Berar Yanai, Orly Schlissel, Muhammad Azem, Neriya Gutgold, Katerina Shulman, Milly Divinsky, Nirit Yarom, Alla Vishkautzan, Chezi Ganzel, Moshe E. GattLidia Arcavi, Eli Marom, Biatrice Uziely, Shoshana Zevin, Hadar Meirow, Osnat Luxenburg, Denize Ainbinder*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives US FDA and EMA allow facilitated regulatory pathways to expedite access to new treatments. Limited supportive data may result in major postapproval variations. In Israel, partly relying on Food and Drug Administration (FDA) and European Medicines Agency (EMA), clinical data are reviewed independently by the Advisory Committee of Drug Registration (ACDR). In this study, the correlation between the number of discussions at the ACDR and major postapproval variations is examined. Design This is an observational retrospective comparative cohort study. Setting Applications with FDA and/or EMA approval at time of assessment in Israel were included. The timeframe was chosen to allow a minimum of 3 years of postmarketing approval experience for potential major label variations. Data regarding the number of discussions at ACDR were extracted from protocols. Data on postapproval major variations were extracted from the FDA and EMA websites. Results Between 2014 and 2016, 226 (176 drugs) applications, met the study criteria. 198 (87.6%) and 28 (12.4%) were approved following single and multiple discussions, respectively. A major postapproval variation was recorded in 129 (65.2%) compared with 23 (82.1%) applications approved following single and multiple discussions, respectively (p=0.002). Increased risk for major variation was found for medicines approved following multiple discussions (HR=1.98, 95% CI: 1.26 to 3.09) with a median time of 1.2 years, applications approved based on phase II trials (HR=2.58, 95% CI: 1.72 to 3.87), surrogate endpoints (HR=1.99, 95% CI: 1.44 to 2.74) and oncologic indications (HR=2.48, 95% CI: 1.78 to 3.45). Conclusions Multiple ACDR discussions associated with limited supportive data are predictive for major postapproval variations. Moreover, our findings demonstrate that approval by the FDA and/or EMA does not pave the way to automatic approval in Israel. In a substantial per cent of the cases, submission of the same clinical data resulted in different safety and efficacy considerations, requiring additional supporting data in some cases or even rejection of the application in others.

Original languageEnglish
Article numbere067313
JournalBMJ Open
Volume13
Issue number5
DOIs
StatePublished - 4 May 2023

Keywords

  • health policy
  • public health
  • risk management
  • therapeutics

Fingerprint

Dive into the research topics of 'Process of drug registration in Israel: The correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA'. Together they form a unique fingerprint.

Cite this